Recruiting

New cancer treatment versus standard chemotherapy for recurring uterine cancer

Plain-English translation of NCT06340568 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated September 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing , a new investigational cancer treatment, to see if it works better than standard chemotherapy drugs for women whose endometrial (uterine) cancer has returned after previous treatment. Some participants will receive the new medication, while others will receive a standard chemotherapy drug that their doctor chooses. The study will follow participants for about 6 months of treatment, then continue tracking their health for several years afterward.

Endometrial cancer that comes back after initial treatment is very difficult to cure with current options. This medication aims to offer a better chance of controlling the cancer, especially for patients whose tumors have specific markers that might make them respond well to this new approach.

Do you qualify?

You likely qualify if…

you are a woman 18 years of age or older
you have been diagnosed with endometrial cancer that has returned or spread
your cancer has specific markers (called HER2 expression) that the study is looking for
your cancer progressed despite at least one previous chemotherapy treatment that included platinum-based drugs
you have received a prior immunotherapy treatment (such as anti-PD-1 or anti-PD-L1 therapy)
you have a life expectancy of at least 12 weeks at the time of screening

You likely don't qualify if…

you have had a small bowel obstruction requiring hospitalization in the past 3 months
you have a history of lung inflammation (interstitial lung disease or pneumonitis) that required steroid treatment
you have fluid buildup around your lungs, abdomen, or heart that needs to be drained
you have serious uncontrolled medical problems that would make it unsafe to participate
you have taken immunosuppressive medications within 2 weeks before starting the study (except for certain allowed corticosteroids)

What participation looks like

If you join this study, you will be randomly assigned to receive either the new medication () or a standard chemotherapy drug of your doctor's choice. You will take your assigned treatment until your cancer stops responding, you experience unacceptable side effects, or you decide to withdraw. You'll have regular visits with the research team for about 6 months, then continue follow-up appointments to monitor your health for up to several more years.

AI-generated summary from trial data · Sep 2, 2026 · Not medical advice

New cancer treatment versus standard chemotherapy for recurring uterine cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations(191 sites)